Mitochondrial DNA: Are some mutations more equal than others?
A large-scale study of mutations in mitochondrial DNA has revealed a subset that do not accumulate with age.
- Department of Biology, Northeastern University, United States
Every cell in our body contains hundreds to hundreds of thousands of mitochondria. These organelles are involved in a myriad of functions, most notably respiration (combining oxygen with food to generate energy) and controlled cell death. Mitochondria are the descendants of prokaryotic cells (similar to bacteria) that became part of primordial eukaryotic cells via a process called endosymbiosis: this means that they have their own double-stranded circular DNA (mtDNA), which is similar to the DNA found in bacteria.
The mitochondria within a cell are constantly proliferating and replicating their mtDNA to compensate for cell growth and division, as well as to offset the removal of damaged mitochondria. Because of their respiration activity, mitochondria produce large amounts of reactive molecules, most notably reactive oxygen species, which damage the mtDNA. If a damaged nucleotide in mtDNA remains unrepaired, this may lead to an incorrect nucleotide being inserted during replication, which is then copied onto the new strand during the next round of replication. This results in permanent double-stranded mutations that accumulate with age as mtDNA molecules are continuously damaged and replicated over the course of a person’s lifespan. Consequently, the mutation rates in mtDNA are about a thousand times higher than in nuclear DNA (Khrapko et al., 1997).
In addition to accumulating with age, mutant mtDNAs are also subject to ‘clonal expansion’ within a cell (Coller et al., 2002). This is mostly a stochastic process in which a random mutated mtDNA molecule multiplies and replaces its peers, resulting in the same mutation appearing in most mtDNA molecules in the cell. Clonal expansions are fundamentally important. If enough mitochondria in a cell contain the same mutation, then this mutation will have a phenotypic effect on the entire cell. Moreover, in the female germline, clonal expansions allow mtDNA mutations to take over the egg cell lineage, potentially resulting in the next generation inheriting the mutation.
Most approaches used to analyze mutations in mtDNA suffer a major drawback as they typically involve in vitro DNA replication, such as PCR. This means that damaged nucleotides – which, in vivo, would have likely been repaired prior to replication or excluded from replication – end up getting erroneously copied and eventually converted into artificial double-stranded mutations that are indistinguishable from genuine ones. Now, in eLife, Scott Kennedy and colleagues from the University of Washington – including Monica Sanchez-Contreras and Mariya Sweetwyne as joint first authors – report how they used a technique called duplex sequencing, which excludes these artificial mutations, to study how mtDNA mutations accumulate with age in mice (Sanchez-Contreras et al., 2023).
The team studied eight different tissues – ranging from the kidney, to the brain and the heart – in young and old mice which were 4.5 and 26 months old. This resulted in an unprecedently large dataset consisting of around 80,000 somatic mtDNA mutations, showing that the rate of accumulation and the composition of mutations vary between different tissues. The highest accumulation rate was in the kidney, where mutations reached the level of one in five mtDNA molecules.
In agreement with previous studies, Sanchez-Contreras et al. observed a high proportion of transition mutations, in which purine (adenine and guanine) and pyrimidine (thymine and cytosine) nucleotide bases are only exchanged for other purines or pyrimidines, respectively. An unusually high proportion of transversion mutations – where a purine changes to a pyrimidine, or vice versa – were also detected. However, unlike the transition mutations, these transversions did not clonally expand and did not accumulate with age in any of the tissues studied. Because new transversions are constantly being generated (mostly through damage caused by reactive oxygen species), lack of accumulation with age implies that these mutations are excluded from being propogated in somatic cells.
Intriguingly, another study also found a high proportion of transversion mutations in the mtDNA of mouse egg cells (Arbeithuber et al., 2020), which was surprising given that the proportion of inherited mutations that are transversions is usually very low. This suggests that transversion mutations are excluded from being propagated in germ cells as well.
Next, Sanchez-Contreras et al. treated mice over 24 months of age with one of two drugs that restore mitochondrial function later in life. Compared to control mice, the researchers found that both drugs reduced the fraction of transversion mutations, irrespective of whether they were detrimental or not. This suggests that transversion mutations are not removed by negative selection. Alternatively, transversion mutations are unlikely to be removed via repair mechanisms as the change in base pairs lies across both mtDNA strands and will therefore not be perceived as an error.
So, why do transversions not expand and accumulate with age? And why do transversion and transition mutations behave differently? Furthermore, Sanchez-Contreras et al. point out that despite using a duplex sequencing approach, it is possible that the transversions they detect might have been potentially generated in vitro from real in vivo DNA damage. Although this may be true (see Abascal et al., 2021 for possible mechanisms), the DNA damage present in vivo should have been at least partially converted (also in vivo) into real transversion mutations. So, why did this not result in the accumulation of transversions with age?
We think we might know the answer to some of these questions, and have developed a model which postulates that there are two broad classes of mtDNA molecules (Figure 1): a ‘stem subpopulation’ of actively replicating mtDNAs which are responsible for renewing the mtDNA pool, and a ‘worker subpopulation’ which are located in actively respiring mitochondria. ‘Stem’ mtDNAs reside in mitochondria that respire less and are therefore protected from reactive oxygen species. Consequently, transversions primarily occur on ‘worker’ mtDNA molecules which rarely replicate, which prevents these mutations from being able to clonally expand and accumulate with age. The model is supported by our analysis of HiFi sequencing data collected by Hon et al., 2020, which shows mtDNA molecules falling into high- and low-damaged groups (Cote-L’Heureu et al., 2023), and is also consistent with a functional study showing ‘replicating’ and ‘respiring’ subpopulations of mitochondria in the cell (Döhla et al., 2022).
Figure 1
Two classes of mtDNA molecules may explain why transversion mutations do not accumulate with age.
Sanchez-Contreras et al. found both transition (light blue crosses) and transversion (black crosses) double-stranded mutations in the mitochondrial DNA (mtDNA) of mice. However, the transversion mutations – which are primarily caused by reactive oxygen species (ROS) – did not accumulate with age. Our own work (Cote-L’Heureu et al., 2023) suggests that cells contain an actively replicating group of mtDNAs – termed the ‘stem’ subpopulation (green) – which are protected from ROS. ‘Stem’ mtDNAs renew themselves and also replenish another group of mtDNAs – termed the ‘worker’ subpopulation (blue) – which are involved in respiration and exposed to higher levels of ROS and therefore acquire more transversion mutations. These mutations, however, do not accumulate because the ‘worker’ mtDNA molecules have a limited replication capacity and are eventually destined for removal (red cross).
In conclusion, the high-fidelity analysis of mtDNA mutations performed by Sanchez-Contreras et al. will become an important resource for future studies. Their data (and similar, more recent work by another group led by Peter Sudmant of Berkeley; Serrano et al., 2023) uncovered an unexpectedly high proportion of transversion mutations in mtDNA molecules, which, unlike transition mutations, did not increase with age.
Work in this field should benefit from the use of single-cell duplex sequencing (Arbeithuber et al., 2020), as well as newer, improved duplex sequencing approaches (Abascal et al., 2021), and long-read mutational analysis (Cote-L’Heureu et al., 2023). These methods could help to test if transversions are real mutations, and how the level of damage varies between mtDNA molecules. Ultimately, this will help researchers to better understand how mtDNA mutations are created, evaded, and inherited, as well as their role in development and aging.
References
-
Frequent intracellular clonal expansions of somatic mtDNA mutations: significance and mechanismsAnnals of the New York Academy of Sciences 959:434–447.https://doi.org/10.1111/j.1749-6632.2002.tb02113.x
Article and author information
Author details
Konstantin Khrapko
Publication history
- Version of Record published: April 19, 2023 (version 1)
Copyright
© 2023, Cote-L’Heureux et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,570
- views
-
- 113
- downloads
-
- 4
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Mitochondrial DNA: Are some mutations more equal than others?
eLife 12:e87194.
https://doi.org/10.7554/eLife.87194
Further reading
-
- Genetics and Genomics
Uncovering the regulators of cellular aging will unravel the complexity of aging biology and identify potential therapeutic interventions to delay the onset and progress of chronic, aging-related diseases. In this work, we systematically compared genesets involved in regulating the lifespan of Saccharomyces cerevisiae (a powerful model organism to study the cellular aging of humans) and those with expression changes under rapamycin treatment. Among the functionally uncharacterized genes in the overlap set, YBR238C stood out as the only one downregulated by rapamycin and with an increased chronological and replicative lifespan upon deletion. We show that YBR238C and its paralog RMD9 oppositely affect mitochondria and aging. YBR238C deletion increases the cellular lifespan by enhancing mitochondrial function. Its overexpression accelerates cellular aging via mitochondrial dysfunction. We find that the phenotypic effect of YBR238C is largely explained by HAP4- and RMD9-dependent mechanisms. Furthermore, we find that genetic- or chemical-based induction of mitochondrial dysfunction increases TORC1 (Target of Rapamycin Complex 1) activity that, subsequently, accelerates cellular aging. Notably, TORC1 inhibition by rapamycin (or deletion of YBR238C) improves the shortened lifespan under these mitochondrial dysfunction conditions in yeast and human cells. The growth of mutant cells (a proxy of TORC1 activity) with enhanced mitochondrial function is sensitive to rapamycin whereas the growth of defective mitochondrial mutants is largely resistant to rapamycin compared to wild type. Our findings demonstrate a feedback loop between TORC1 and mitochondria (the TORC1–MItochondria–TORC1 (TOMITO) signaling process) that regulates cellular aging processes. Hereby, YBR238C is an effector of TORC1 modulating mitochondrial function.
-
- Genetics and Genomics
- Neuroscience
Adenine phosphoribosyltransferase (APRT) and hypoxanthine-guanine phosphoribosyltransferase (HGPRT) are two structurally related enzymes involved in purine recycling in humans. Inherited mutations that suppress HGPRT activity are associated with Lesch–Nyhan disease (LND), a rare X-linked metabolic and neurological disorder in children, characterized by hyperuricemia, dystonia, and compulsive self-injury. To date, no treatment is available for these neurological defects and no animal model recapitulates all symptoms of LND patients. Here, we studied LND-related mechanisms in the fruit fly. By combining enzymatic assays and phylogenetic analysis, we confirm that no HGPRT activity is expressed in Drosophila melanogaster, making the APRT homolog (Aprt) the only purine-recycling enzyme in this organism. Whereas APRT deficiency does not trigger neurological defects in humans, we observed that Drosophila Aprt mutants show both metabolic and neurobehavioral disturbances, including increased uric acid levels, locomotor impairments, sleep alterations, seizure-like behavior, reduced lifespan, and reduction of adenosine signaling and content. Locomotor defects could be rescued by Aprt re-expression in neurons and reproduced by knocking down Aprt selectively in the protocerebral anterior medial (PAM) dopaminergic neurons, the mushroom bodies, or glia subsets. Ingestion of allopurinol rescued uric acid levels in Aprt-deficient mutants but not neurological defects, as is the case in LND patients, while feeding adenosine or N6-methyladenosine (m6A) during development fully rescued the epileptic behavior. Intriguingly, pan-neuronal expression of an LND-associated mutant form of human HGPRT (I42T), but not the wild-type enzyme, resulted in early locomotor defects and seizure in flies, similar to Aprt deficiency. Overall, our results suggest that Drosophila could be used in different ways to better understand LND and seek a cure for this dramatic disease.
